- Home
- RFMZ vs PROF Comparison
RFMZ vs PROF Comparison
Compare RFMZ & PROF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RFMZ | PROF |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 286.9M | 248.8M |
| IPO Year | 2020 | 2017 |
Fundamental Metrics
Financial Performance| Metric | RFMZ | PROF |
|---|---|---|
| Price | $11.55 | $6.90 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $11.14 |
| AVG Volume (30 Days) | 121.5K | ★ 240.2K |
| Earning Date | 01-01-0001 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.89 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $16,098,000.00 |
| Revenue This Year | N/A | $71.10 |
| Revenue Next Year | N/A | $58.54 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 50.73 |
| 52 Week Low | $11.31 | $4.91 |
| 52 Week High | $13.70 | $8.95 |
Technical Indicators
Market Signals| Indicator | RFMZ | PROF |
|---|---|---|
| Relative Strength Index (RSI) | 31.66 | 61.97 |
| Support Level | $11.37 | $6.51 |
| Resistance Level | $13.57 | $7.13 |
| Average True Range (ATR) | 0.23 | 0.35 |
| MACD | -0.01 | 0.15 |
| Stochastic Oscillator | 21.21 | 78.19 |
Price Performance
Historical ComparisonAbout RFMZ RiverNorth Flexible Municipal Income Fund II Inc.
RiverNorth Flex Muni Income Fund II Inc is a diversified, closed-end management investment company. Its primary investment objective is to seek current income exempt from regular U.S. federal income taxes. The fund's secondary investment objective is total return.
About PROF Profound Medical Corp.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.